6 research outputs found
Nicotine-Free E-Cigarettes Might Promote Tobacco Smoking Reduction Better Than Nicotine Delivery Devices: Results of a Double-Blind Randomized Controlled Trial at 1 Year
The purpose of the present study was to determine whether the use of e-cigarettes to aid in quitting contributed to the increase in the pulmonary health of chronic smokers. The efficacy of e-cigarettes to support a successful smoking cessation attempt was also investigated. A total of 210 smokers (78 women) were enrolled in a screening program for the early detection of lung cancer and distributed in three arms: nicotine e-cigarette plus support, nicotine-free e-cigarette plus support, and support. Results showed that participants in the nicotine e-cigarette arm had a significant and fast decrease in daily cigarettes, but that later they resume smoking more than the other two groups. Conversely, participants in the other two arms showed similar daily consumption at the two evaluation points. Among abstinent participants, only 12.5% reported cough, while 48% of current smokers had pulmonary symptoms. Our study suggests that, in the long run, the use of a nicotine-free liquid may favor reducing smoking and could be considered a good option in a clinical setting
N-Acetylcysteine Regenerates In Vivo Mercaptoalbumin
Human serum albumin (HSA) represents the most abundant plasma protein, with relevant antioxidant activity due to the presence of the sulfhydryl group on cysteine at position 34 (Cys34), the latter being one of the major target sites for redox-dependent modifications leading to the formation of mixed disulfide linkages with low molecular weight thiols. Thiolated forms of HSA (Thio-HSA) may be useful as markers of an unbalanced redox state and as a potential therapeutic target. Indeed, we have previously reported that albumin Cys34 can be regenerated in vitro by N-Acetylcysteine (NAC) through a thiol-disulfide breaking mechanism, with a full recovery of the HSA antioxidant and antiplatelet activities. With this case study, we aimed to assess the ability of NAC to regenerate native mercaptoalbumin (HSA-SH) and the plasma antioxidant capacity in subjects with redox unbalance, after oral and intravenous administration. A placebo-controlled crossover study, single-blinded, was performed on six hypertensive subjects, randomized into two groups, on a one-to-one basis with NAC (600 mg/die) or a placebo, orally and intravenously administered. Albumin isoforms, HSA-SH, Thio-HSA, and glutathione levels were evaluated by means of mass spectrometry. The plasma antioxidant activity was assessed by a fluorimetric assay. NAC, orally administered, significantly decreased the Thio-HSA levels in comparison with the pre-treatment conditions (T0), reaching the maximal effect after 60 min (â24.7 ± 8%). The Thio-HSA reduction was accompanied by a concomitant increase in the native HSA-SH levels (+6.4 ± 2%). After intravenous administration of NAC, a significant decrease of the Thio-HSA with respect to the pre-treatment conditions (T0) was observed, with a maximal effect after 30 min (â68.9 ± 10.6%) and remaining significant even after 6 h. Conversely, no effect on the albumin isoforms was detected with either the orally or the intravenously administered placebo treatments. Furthermore, the total antioxidant activity of the plasma significantly increased after NAC infusion with respect to the placebo (p = 0.0089). Interestingly, we did not observe any difference in terms of total glutathione corrected for hemoglobin, ruling out any effect of NAC on the intracellular glutathione and supporting its role as a disulfide-breaking agent. This case study confirms the in vitro experiments and demonstrates for the first time that NAC is able to regenerate mercaptoalbumin in vivo, allowing us to hypothesize that the recovery of Cys34 content can modulate in vivo oxidative stress and, hopefully, have an effect in oxidative-based diseases
Real-World Effectiveness of Calcitonin Geneâ Related Peptide-Binding Monoclonal Antibodies for Migraine Prevention: A Systematic Review
Background: Migraine is a neurological disease with a high incidence. The new anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs) have demonstrated effectiveness in preventing episodic and chronic migraine.
Objective: To collect evidence of the real-world effectiveness of anti-CGRP mAbs by assessing outcomes such as reduction in monthly migraine days (MMDs), reduction in monthly headache days (MHDs), and percentage of patients having a 50% reduction in MMDs.
Data Sources: The PubMed database was searched for the period from inception to October 20, 2021.
Study Selection and Data Extraction: Of interest for this review were studies that evaluated the real-world effectiveness of anti-CGRP mAbs in terms of MMDs and reduction in MHDs. The search terms included âmigraineâ, âmonthly migraine daysâ, and various drug names. The data are reported in terms of patientsâ baseline characteristics and treatment effectiveness.
Data Synthesis: A total of 46 studies were evaluated, of which 30 (enrolling a total of 4273 patients across 10 countries) were included in the systematic review. The greatest absolute reduction in MMD was from 20.4 at baseline to 10.7 after 3 months of treatment. After 6 months, the greatest absolute difference was 10, relative to baseline. The largest absolute reduction in MHD at 3 months was from 22 to 8, whereas at 6 months, the greatest absolute reduction in MHD was 13. The treatment could be considered clinically effective (â„ 50% reduction in MMDs) for 41% of patients at 3 months and about 44% of patients at 6 months.
Conclusions: Despite substantial variability in baseline values, this review confirmed the effectiveness of anti-CGRP mAbs, which yielded important clinical reductions in both MMDs and MHDs.
Keywords: anti-CGRP mAbs, migraine, effectiveness, real-life, prevention
RĂSUMĂ
Contexte : La migraine est une maladie neurologique à incidence élevée. Le nouvel anticorps monoclonal qui se lie au peptide lié au gÚne de la calcitonine (AcM anti-CGRP) a démontré son efficacité pour prévenir les migraines épisodiques et chroniques.
Objectif : Recueillir des Ă©lĂ©ments probants concernant lâefficacitĂ© rĂ©elle des AcM anti-CGRP en Ă©valuant des rĂ©sultats comme la rĂ©duction du nombre de jours de migraine par mois (JMM), la rĂ©duction du nombre de jours de cĂ©phalĂ©es par mois (JCM) ainsi que le pourcentage de patients ayant une rĂ©duction de 50 % du nombre de JMM.
Sources des donnĂ©es : La base de donnĂ©es PubMed a Ă©tĂ© utilisĂ©e pour mener une recherche pour la pĂ©riode allant du dĂ©but jusquâau 20 octobre 2021.
SĂ©lection des Ă©tudes et extraction des donnĂ©es : Les auteurs de la revue se sont intĂ©ressĂ©s aux Ă©tudes qui avaient Ă©valuĂ© lâefficacitĂ© rĂ©elle des AcM anti-CGRP en termes de rĂ©duction du nombre de JMM et du nombre de JCM. Les termes de recherche comprenaient « migraine », « jours de migraine par mois » et divers noms de mĂ©dicaments. Les donnĂ©es sont rapportĂ©es en termes de caractĂ©ristiques de base des patients et dâefficacitĂ© du traitement.
SynthĂšse des donnĂ©es : Au total, 30 des 46 Ă©tudes rĂ©pondant aux critĂšres dâinclusion (comprenant un total de 4273 patients dans 10 pays) ont Ă©tĂ© retenues pour la revue systĂ©matique. La rĂ©duction absolue de JJM la plus importante Ă©tait de 20,4 (la base de rĂ©fĂ©rence) Ă 10,7 aprĂšs 3 mois de traitement. AprĂšs 6 mois, la diffĂ©rence absolue la plus importante Ă©tait de 10 par rapport Ă la base de rĂ©fĂ©rence. La rĂ©duction absolue de JCM la plus importante Ă trois mois Ă©tait de 22 Ă 8, alors quâĂ 6 mois, la rĂ©duction absolue de JCM la plus importante Ă©tait de 13. Le traitement pouvait ĂȘtre considĂ©rĂ© comme cliniquement efficace (â„50 % de rĂ©duction de JMM) pour 41 % des patients Ă 3 mois et environ 44 % des patients Ă 6 mois.
Conclusions : MalgrĂ© la variabilitĂ© importante des valeurs de la base de rĂ©fĂ©rence, cet examen confirme lâefficacitĂ© des AcM anti-CGRP, qui ont donnĂ© lieu Ă une rĂ©duction importante dâun point de vue clinique du nombre de JMM et de JCM.
Mots-clés : anticorps monoclonal qui se lie au peptide lié au gÚne de la calcitonine, anti-CGRP mAbs, AcM anti-CGRP, migraine, efficacité, réalité, préventio
Recommended from our members
Effect of metformin and lifestyle intervention on adipokines and hormones in breast cancer survivors: a pooled analysis from two randomized controlled trials.
PURPOSE: We investigated the effect of metformin and lifestyle intervention on metabolic, inflammatory, and steroid biomarkers of breast cancer (BC) recurrence risk in two intervention trials among BC survivors with overweight or obesity. METHODS: Baseline and follow-up serum samples collected during the two trials were analyzed and data pooled. The USA trial (Reach for Health) included postmenopausal BC survivors (nâ=â333) randomly assigned to 6-month metformin vs placebo and lifestyle intervention (LSI) vs control (2âĂâ2 factorial design). The Italian trial (MetBreCS) included BC survivors (nâ=â40) randomized to 12-month metformin vs placebo. Insulin resistance (HOMA-IR), adipokines, cytokines, and steroids were measured. RESULTS: Metformin compared to placebo showed a favorable decrease in leptin (- 8.8 vs - 3.5 ng/mL; pâ<â0.01) and HOMA-IR (- 0.48 vs - 0.25; pâ=â0.03), and an increase in SHBG (2.80 vs 1.45 nmol/L; pâ<â0.01). Excluding women taking aromatase inhibitors, metformin (nâ=â84) compared to placebo (nâ=â99) decreased estradiol (- 4 vs 0 pmol/L; pâ<â0.01), estrone (- 8 vs 2 pmol/L; pâ<â0.01) and testosterone (- 0.1 vs 0 nmol/L-; pâ=â0.02). LSI favorably affected adiponectin (0.45 vs - 0.06 ug/mL; pâ<â0.01), leptin (- 10.5 vs - 4.4 ng/mL; pâ<â0.01), HOMA-IR (- 0.6 vs 0.2; pâ=â0.03), and SHBG (2.7 vs 1.1 nMol/L; pâ=â0.04) compared to controls. The strongest impact was observed combining metformin with LSI on adipokines, CRP, SHBG, and estrogens. CONCLUSIONS: Supportive healthy lifestyle programs combined with metformin to achieve maximal risk reduction among BC cancer survivors are recommended, especially for those with obesity in menopause
Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19
Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis
To assess the evidence on SARS-CoV2 infection and Covid-19 in relation to deficiency and supplementation of vitamin D, we conducted a systematic review up to April 2021. We summarised data from 38 eligible studies, which presented risk estimates for at least one endpoint, including two RCT and 27 cohort-studies: 205565 patients with information on 25OHD status and 2022 taking vitamin D supplementation with a total of 1197 admitted to the ICU or who needed invasive mechanical ventilation or intubation and hospital stay, and more than 910 Covid-19 deaths. Primary outcomes were severity and mortality and the main aim was to evaluate the association with vitamin D supplementation. Random effects models showed that supplementation was associated with a significant lower risk of both Covid-19 severe disease (SRR 0.38, 95% CI 0.20-0.72, 6 studies) and mortality (SRR 0.35, 95% CI 0.17-0.70, 8 studies). There were no statistically significant dose differences between studies: summary estimates with regular doses remain statistically significant, suggesting that higher doses are not necessary. For patients on vitamin D supplementation, a greater reduction in mortality risk emerged in older individuals and at higher latitudes. Regarding the quality of studies, assessed using the New Castle-Ottawa quality scale, the analysis revealed in most cases no statistically significant differences between low, medium or high quality studies. We found significant associations of vitamin D supplementation with Covid-19, encompassing risks of disease worsening and mortality, especially in seasons characterized by 25OHD deficiency and with not severe patients. Dedicated randomized clinical studies are encouraged to confirm these results